Market Scenario Lichen sclerosus is a medical condition characterized by patchy, white skin which is thinner than the normal skin. This medical condition can affect skin of any body part. However, a majority of the cases are reported for the skin of the vulva, foreskin of the penis and the skin around the anus. Sometimes the disease related effects improves by themselves. On the other hand, treatment procedures can be devised depending upon the severity of the disease. Some of the common symptoms of the disease are inclusive of pruritus, blotchy, bruising, bleeding, blistering, and others. Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/4265 The treatment procedures for the disease are inclusive of application of drugs and surgery. The drugs against lichen sclerosus can be administered via topical, oral, IV routes and others. Increasing prevalence of skin diseases is one of the major drivers for market growth during the forecast period. In 2013, according to the American Osteopathic College of Dermatology, American spent approximately USD 75 billion was spent on skin disease. It is estimated that anyone be diagnosed with lichen sclerosus, however, a majority of the effected population is inclusive of menopausal women. In 2015, the United Census Bureau stated that the global geriatric population for females will reach 4,139 million by 2030 from 3,601 million in 2015. Moreover, factors such as rising healthcare expenditure and increasing research and development expenses by the market key players drives the market growth. However, lack of specific treatments and lack of awareness for the disease is estimated to restraint the market growth during forecast period. The global Lichen Sclerosus Treatment Market Trends is expected to grow at a CAGR of 7.8% during the forecast period and is estimated to reach USD 150 million by 2023. Key Players in the Global Lichen Sclerosus Treatment Market Some of the key players in this market are AstraZeneca plc, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., Pfizer Inc., Sandoz AG (Novartis AG), Sanofi S.A., Valeant Pharmaceuticals, and Zylera Pharmaceuticals. Segments
The global sclerosus treatment market is segmented on the basis of type of treatment, which includes drug therapy and surgery. The drug therapy is further segmented into corticosteroid, immune modulating drugs, retinoid like agents, and others. Surgery is further segmented into laser surgery, circumcision, and others. On the basis of mode of administration, the market is segmented into oral, topical, IV (Intravenous), and others. Oral is further segmented into tablets, capsule, and others. The topical administration is further segmented into creams, ointment, and others. On the basis of end user, the market is segmented into hospitals, dermatology clinics, pharmacies, and others. read more @ https://www.marketresearchfuture.com/reports/lichen-sclerosus-treatment-market-4265 About US: Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.